Nextech3D.ai Accelerates Eventdex Integration; Expands AI Matchmaking and Achieves Milestone Production of 800 Interactive Floor Plans in 2025 Artificial Intelligence Investing
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025 Life Science Investing
Rakovina Therapeutics' President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit Life Science Investing
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position Life Science Investing
NRx Pharmaceuticals, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update Life Science Investing
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program Life Science Investing
Charles River Laboratories to Present at Jefferies Global Healthcare Conference Life Science Investing
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit Life Science Investing
BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease Life Science Investing
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy Life Science Investing
Incyte Announces Positive CHMP Opinion for Minjuvi® for the Treatment of Relapsed or Refractory Follicular Lymphoma Life Science Investing
